AEOL 10150

Drug Profile

AEOL 10150

Alternative Names: AEOL-10150; MnTDEIP

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Duke University; National Jewish Medical and Research Center
  • Developer Aeolus Pharmaceuticals Inc; National Institutes of Health (USA); National Jewish Medical and Research Center; United States Army Medical Research Institute of Chemical Defense; University of Colorado at Denver
  • Class Oxidoreductases; Porphyrins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Free radical scavengers; Oxygen radical scavengers; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Idiopathic pulmonary fibrosis; Acute radiation syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute radiation syndrome
  • Preclinical Acute lung injury; Cancer; Gastrointestinal disorders; Idiopathic pulmonary fibrosis; Lung disorders; Poisoning; Radioprotection; Skin disorders
  • Suspended Amyotrophic lateral sclerosis
  • Discontinued Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetes mellitus; Mucositis; Spinal cord injuries; Stroke

Most Recent Events

  • 19 Sep 2016 Preclinical data released by Aeolus Pharmaceuticals
  • 06 Sep 2016 Pharmacodynamics data from a preclinical trial in Acute lung injury released by Aeolus
  • 15 Aug 2016 AEOLUS Pharmaceuticals intends to file an IND with the US FDA for Idiopathic Pulmonary Fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top